ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
1. ANIP's Q4 adjusted EPS rose to $1.63, exceeding $1.44 consensus. 2. Sales surged 44.8% to $190.57 million, beating estimates. 3. Net revenues for rare diseases increased 108.5% to $87.0 million. 4. 2025 revenue guidance raised to $756-$776 million, above prior $739-$759 million. 5. Stock rose 10.41% to $60.26 following these results.